On June 24, 2025, the 23rd China International Pharmaceutical Ingredients Exhibition (CPHI China 2025) kicked off at the Shanghai New International Expo Center. Hangzhou Huarong Pharmaceutical Co., Ltd. participated in the exhibition with its core active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. This year's exhibition attracted more than 3,500 enterprises worldwide and over 100,000 professional visitors.
With the theme of "Innovation-Driven Green Intelligent Manufacturing", Huarong Pharmaceutical set up a 30-square-meter standard booth, focusing on displaying its core broad-spectrum antibacterial product - Chloramphenicol (CAS: 56-75-7) API. Due to its high purity and low impurity characteristics, this product has attracted the attention of merchants from Southeast Asia and the Middle East, with its overseas market share increasing by 10% annually.
During the exhibition, the production process optimization achievements demonstrated by Huarong Pharmaceutical are in line with the "Green Pharmaceutical Initiative", helping partners reduce costs and increase efficiency.
Relying on its product quality and cost-effectiveness advantages, Huarong Pharmaceutical has become a negotiation target for small and medium-sized overseas purchasers. In the first two days of the exhibition, it received more than 500 professional visitors, and multiple negotiations have entered the follow-up docking stage.
Huarong Pharmaceutical has an 80-mu standardized production base in Hangzhou. This time, it takes the CPHI exhibition as an opportunity to expand overseas cooperation channels. The general manager stated that the company will continue to provide high-quality API products.
It is reported that CPHI China 2025 will last until June 26. Huarong Pharmaceutical has set up a negotiation area and a consultation desk in Hall E10 to provide product consultation and cooperation docking services for merchants.
